Stage IV Lung Adenocarcinoma Discovered After Cancer Cells Were Found in a Stroke Clot

This lung cancer diagnosis at a glance

Stage at diagnosis
Stage IV
Subtype
Adenocarcinoma
Biomarkers
PD-L1 high (TPS 90%); no actionable driver alteration
Sex
male
Spread to
brain
Treatment
immunotherapy
Outcome
In Memory

Treatment course, step by step

  1. Started pembrolizumab as first-line treatment after testing showed PD-L1 expression of 90% and no actionable driver alteration.

What happened, in summary

A 76-year-old man was hospitalized with a severe stroke causing left-sided weakness, visual loss, and speech difficulty. He underwent mechanical thrombectomy to reopen the blocked right middle cerebral artery. Brain imaging showed the stroke but no brain metastases at that time.

Unexpectedly, examination of the removed clot found malignant epithelial cells. Further testing supported a pulmonary adenocarcinoma, and chest CT then revealed a large left lower-lobe mass with mediastinal lymph-node involvement and invasion of a pulmonary vein. The cancer was Stage IV. Testing showed very high PD-L1 expression at 90%, a TP53 mutation, and no actionable driver alteration.

Pembrolizumab was started as first-line immunotherapy. Although his neurologic function initially improved enough for discharge with mild residual deficits, new frontal brain metastases appeared and his overall condition worsened rapidly. He died 51 days after the index stroke. The case illustrates an unusual presentation in which the stroke clot itself provided the first clue to an otherwise occult lung cancer.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar lung cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more lung cancer stories